Wednesday, June 19, 2013 Last update: 7:36 AM
Company Tech News as it Breaks
Trade Events
Idera Pharmaceuticals, Inc.
News articles for Idera Pharmaceuticals, Inc.:
Wednesday, June 5, 2013
- Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque PsoriasisIdera Pharmaceuticals (NASDAQ: IDRA) today announced that it has initiated dosing in a randomized, double-blind, placebo-controlled Phase 2 trial of IMO-8400 in patients with moderate to severe plaque ... read more
Wednesday, May 15, 2013
- Idera Pharmaceuticals Reports First Quarter 2013 Financial ResultsIdera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2013. ... read more
Wednesday, May 8, 2013
- Idera Announces Presentation of Positive Data from Phase 2 Trial of TLR 7 and 9 Antagonist in Patients with Moderate-to-Severe Plaque PsoriasisIdera Pharmaceuticals (NASDAQ: IDRA) today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis ... read more
Tuesday, May 7, 2013
- Idera Pharmaceuticals Announces Closing of Common Share OfferingIdera Pharmaceuticals (NASDAQ: IDRA) announced today the closing of its previously announced $16.5 million underwritten public offering of (i) 17,500,000 shares of common stock and related warrants to ... read more
Monday, April 1, 2013
- Idera Announces Clinical Development Progress in Its Autoimmune Diseases ProgramIdera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that it has completed dosing in its Phase 1 trial of IMO-8400 in healthy subjects. In addition, the Company announced that ... read more
Monday, March 11, 2013
- Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results and Provides Update on Autoimmune Disease ProgramIdera Pharmaceuticals, Inc. (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2012. ... read more
Saturday, March 2, 2013
- Idera Announces Presentation at AAD Annual Meeting Demonstrating Toll-like Receptor Antagonists Normalize Expression of Inflammatory Genes in Psoriasis ModelIdera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the presentation of new data showing that its selective Toll-like receptor antagonists, IMO-3100 and IMO-8400, normalized the gene expression of ... read more
Tuesday, February 26, 2013
- Idera Pharmaceuticals Announces Presentation at American Academy of Dermatology Annual MeetingIdera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company developing Toll-like receptor targeted drug candidates for the treatment of autoimmune diseases, today announced a presentation of preclinical ... read more
Tuesday, February 5, 2013
- Idera to Present at the 15th Annual BIO CEO and Investor ConferenceIdera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company developing Toll-like receptor targeted product candidates for the treatment of autoimmune diseases and as vaccine adjuvants, today ... read more